{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barth DA"],"funding":["Austrian Science Fund FWF"],"pagination":["840207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010871"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response.<h4>Methods</h4>Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subt"],"journal":["Frontiers in immunology"],"pubmed_title":["Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study."],"pmcid":["PMC9010871"],"funding_grant_id":["W 1226","DK-MCD W1226","Hertha-Firnberg Grant T1112-B"],"pubmed_authors":["Posch F","Ahyai SA","Szkandera J","Absenger G","Spiegelberg JA","Bauernhofer T","Pichler M","Smolle MA","Gerger A","Barth DA","Jost PJ","Stradner MH","Riedl JM","Hutterer GC","Madl T","Kargl J","Stanzer S","Klec C"],"additional_accession":[]},"is_claimable":false,"name":"Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.","description":"<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response.<h4>Methods</h4>Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subt","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-05T13:24:42.739Z","creation":"2025-04-05T13:24:42.739Z"},"accession":"S-EPMC9010871","cross_references":{"pubmed":["35432362"],"doi":["10.3389/fimmu.2022.840207"]}}